Medincell's partner teva presented new efficacy, safety, and tolerability data from pivotal phase 3 of olanzapine lai for adult patients diagnosed with schizophrenia

Montpellier, france--(business wire)--teva presented at ecnp 2024* new positive efficacy, safety, and tolerability results for phase 3 solaris trial evaluating olanzapine lai (tv-‘749 / mdc-tjk) in adult patients diagnosed with schizophrenia. richard malamut, chief medical officer of medincell, said: “in addition to publishing the positive efficacy results for the primary and secondary endpoints of the solaris study, the data presented by teva unveiled the three doses evaluated, which align wit.
TEVA Ratings Summary
TEVA Quant Ranking